RxDoctor Payments Data

Pierre Estime

Family Medicine · New Britain, CTNPI 1023089315

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novo Nordisk at 43.6% of the total. Reporting peaked in 2019 at $1,357 and has fallen 97.6% since, to $33 in 2023.

$2,712in general payments, 2019–2025

Across 174 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$295
  • Pfizer$265
  • Boehringer Ingelheim$233
  • Merck$197
  • Lilly USA, LLC$124
  • plus $416 from 11 others

What the payments were for

  • Food & beverage$2,712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,712 in reported general payments places this provider in the 80th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut →

Other family medicine in New Britain

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →